600+ in-depth articles on Japanese heavy-ion therapy, immunotherapy, and precision medicine — stay current on international care and regenerative medicine.
The FDA has approved a new breast cancer drug by Celcuity, but rollout concerns remain. Here is what international patients considering Japan should understand before acting.
Eli Lilly Japan has launched a new liquid suspension form of baricitinib (Ormient). Here's what it means for patients considering treatment in Japan.
The FDA has granted its first approval for a wearable on-body injectable anticancer device. Here's what cancer patients considering treatment abroad should know.
A plain-language summary of recent pembrolizumab-related developments—FDA review of a new combination, next-gen competitors, and biosimilar program changes—and what international patients should consider next.
The FDA has approved Celcuity's first breast cancer drug. Here's what this US regulatory milestone may — and may not — mean for patients exploring treatment options in Japan.
A new digital system connecting hospital documentation and insurance in Japan — what it means for patients considering cancer care at major Japanese centers.
The EU has approved Enhertu for previously treated HER2-positive metastatic solid tumours — the first tumour-agnostic HER2-directed antibody drug conjugate approval. Here's what it means for patients considering treatment options.
The FDA has approved ropeginterferon alfa-2b-njft (BESREMi Pen™) for polycythemia vera in the U.S. Here's what patients considering overseas treatment should know.
Lupin has received a US FDA tentative approval for a prostate cancer drug — what this regulatory step means, and what patients considering treatment in Japan should know.
The FDA has approved Aprepitant Injectable Emulsion by Azurity Pharmaceuticals. Here is what cancer patients considering treatment in Japan should know.
Ferring Pharma's Adstiladrin intravesical solution, a gene therapy for BCG-unresponsive bladder cancer, has received regulatory approval in Japan — here's what it means for patients considering treatment abroad.
Elevar Therapeutics CEO expects an FDA decision on a first-line liver cancer drug around July 23, 2026, with no outstanding review issues — what this may mean for patients exploring treatment options.
The FDA has approved new oncology drugs, imaging agents, and diagnostics. Here is what it means for patients considering treatment in Japan.
GSK's momelotinib has received Orphan Drug Designations in both the US and EU for VEXAS syndrome — a regulatory milestone, not yet a treatment approval. Here's what it means for patients.
The FDA has approved a Guardant Health companion diagnostic to help identify eligible patients for a new Boehringer Ingelheim cancer drug. Here's what it means for patients exploring treatment options.
Sawai Pharmaceutical announced expanded indications and dosage approval for Lenalidomide Capsules in Japan — here is what it may mean for patients considering treatment there.
One of Japan's top cancer hospitals has partnered with J&J to advance clinical trials — here's what it may mean for patients considering treatment in Japan.
Replimune has been given a third opportunity to seek US approval for a skin cancer drug. Here's what this regulatory development means for patients considering treatment in Japan.
RadioMedix has received U.S. FDA approval for a generic Ga-68 PSMA-11 imaging agent for prostate cancer. Here's what it means for patients considering care abroad.
Merck's Welireg and Keytruda combination has received regulatory approval for kidney cancer patients following surgery. Here's what it means if you're exploring treatment options.
The FDA has approved a new AbbVie drug for a rare blood cancer. Here's what international patients considering treatment in Japan should know before taking next steps.
Japan's pharmaceutical advisory committee has recommended approval for AstraZeneca's anticancer medicine Etocama and 10 other items — what this means for patients considering treatment in Japan.
The FDA has approved an ADC therapy developed by ImmunoGen (AbbVie) for a rare blood cancer. Here's what this means for patients considering treatment abroad, including in Japan.
The FDA has issued full approval for imatinib (Gleevec) in adjuvant GIST treatment. Here is what this U.S. decision may mean for patients considering care in Japan.
The FDA has approved an AbbVie antibody-drug conjugate (ADC) for an ultra-rare blood cancer. Here's what this means for patients considering treatment options in Japan.
AbbVie's DECNUPAZ has received FDA approval for blood cancer. Here's what this means for patients considering treatment options in Japan.
Replimune has resubmitted a cancer therapy for FDA approval after two prior rejections. Here's what patients considering treatment in Japan should know right now.
The FDA has granted accelerated approval to sonrotoclax (Begalzi) for relapsed or refractory mantle cell lymphoma. Here's what it means for patients exploring treatment options in Japan.
T-cell metabolic switching is key to generating sustained immune memory T-cells and is associated with anti-tumor responses, offering new hope for cancer immunotherapy.
The patented six-cell combination technology developed by founder Dr. Tsuneo Kuramochi (deceased) is now carried forward by Dr. Toshihide Aso at Dojin Clinic, providing new hope for advanced cancer patients.